Episode 26. Management of Newly Diagnosed Hodgkin's Lymphoma Blood Cancer Talks

In this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University.
Link for our Blood Cancer Talks Survey: https://bit.ly/BCTS
Here are the key trials we discussed:
1. RATHL Trial (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):
https://pubmed.ncbi.nlm.nih.gov/27332902/
 
2. S0816 (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):
https://pubmed.ncbi.nlm.nih.gov/27069074/
 
3. ECHELON-1 (Replacing Bleomycin by Brentuximab Vedotin in Advanced Hodgkin’s Lymphoma):
https://pubmed.ncbi.nlm.nih.gov/29224502/
https://pubmed.ncbi.nlm.nih.gov/35830649/
 
4. BREACH (BV-AVD vs ABVD for Early Stage Unfavorable Hodgkin’s Lymphoma):
https://pubmed.ncbi.nlm.nih.gov/35867960/
 
5. S1826 (Nivo-AVD vs BV-AVD in Advanced Hodgkin’s Lymphoma):
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA4
 
6. FIL-ROUGE (PET-adapted ABVD vs Dose-Intensified ABVD):
https://onlinelibrary.wiley.com/doi/10.1002/hon.3163_4
 
7.  HD21 (BRECADD vs EBEACOPP in Advanced Hodgkin’s Lymphoma):
https://onlinelibrary.wiley.com/doi/10.1002/hon.3196_LBA5